The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Research Shows Benefits of Eliquis Over Warfarin For Atrial Fibrillation Patients
While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.
Post-Ablation Recurrence Risk Increases with BMI in Patients with Atrial Fibrillation
Analyses of patient records indicate that obesity increases the risk of recurrence among patients who undergo ablation for atrial fibrillation but suggest that sustained weight loss can reduce the risk.
Sports Medicine: High Volume Training Improves Arterial Function
Highly trained female athletes showed no sign of a negative effect on their hearts after intense workouts--contradicting studies that found such maximal excercise can be counter-productive, researchers said at the AHA meeting in Orlando, FL.
Algae-Based Injectable Implant Device Improved Heart Function
Injecting globs of a biopolymer based on brown algae into the heart muscle of patients with advanced heart disease helped halt or reverse disease. The procedure is meant to thicken the ventricle wall. That reduces pumping stress.
Novel Reversal Agent Found Effective
An investigational drug called andexanet alfa that can reverse the anticoagulant effects of FXa inhibitors met all primary and secondary efficacy endpoints, researchers said in a late-breaking clinical trial report at the AHA meeting in Orlando.
Evaluating the Risk/Benefit Profile of Ticagrelor
November 10th 2015Analysis of data from the PEGASUS-TIMI 54 trial showed high rates of treatment discontinuation due to adverse events such as bleeding and dyspnea, with the highest rate occurring in the first year of treatment. Patients who stuck with treatment experienced a reduction in cardiovascular death, myocardial infarction, and stroke.
PROACT-4 Trial on Benefits of Troponin Testing for Acute Cardiovascular Disease
November 10th 2015Chest pain is one of the most common reasons that patients visit the emergency room, and the use of troponin testing can help cut down the time between first medical contact to final patient disposition.
OK to Give tPA to Stroke Patients on NOACs
Intravenous administration of tissue plasminogen activator (tPA) appears safe in selected patients who were already on novel oral anticoagulants (NOACs) a team reported at the American Heart Association Annual Scientitific Session in Orlando, FL.
CHA2DS2-VASc Scores Useful Even When Patients Do Not Have Atrial Fibrillation
The scoring system known as CHA2DS2-VASc is commonly used as a clinical guideline for assessing ischemic stroke risk in patients with atrial fibrillation (AF). A research team from Santiago, Chile found it can also predict vascular dysfunction and cardiovascular events in high-risk patients who do not have AF.